TW202210503A - 用於過繼細胞療法之多肽 - Google Patents

用於過繼細胞療法之多肽 Download PDF

Info

Publication number
TW202210503A
TW202210503A TW110118988A TW110118988A TW202210503A TW 202210503 A TW202210503 A TW 202210503A TW 110118988 A TW110118988 A TW 110118988A TW 110118988 A TW110118988 A TW 110118988A TW 202210503 A TW202210503 A TW 202210503A
Authority
TW
Taiwan
Prior art keywords
seq
sequence
polypeptide
cell
cells
Prior art date
Application number
TW110118988A
Other languages
English (en)
Chinese (zh)
Inventor
勞德拉 馬克 瑪蒂尼斯
賽門 伯恩沙因
Original Assignee
英商圭爾醫療有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 英商圭爾醫療有限公司 filed Critical 英商圭爾醫療有限公司
Publication of TW202210503A publication Critical patent/TW202210503A/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/418—Antigens related to induction of tolerance to non-self
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW110118988A 2020-05-26 2021-05-26 用於過繼細胞療法之多肽 TW202210503A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB2007842.4A GB202007842D0 (en) 2020-05-26 2020-05-26 Polypeptide useful in adoptive cell therapy
GB2007842.4 2020-05-26

Publications (1)

Publication Number Publication Date
TW202210503A true TW202210503A (zh) 2022-03-16

Family

ID=71406309

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110118988A TW202210503A (zh) 2020-05-26 2021-05-26 用於過繼細胞療法之多肽

Country Status (9)

Country Link
US (1) US20230183311A1 (https=)
EP (1) EP4157318A1 (https=)
JP (1) JP2023527049A (https=)
CN (1) CN115955977A (https=)
AU (1) AU2021279184A1 (https=)
CA (1) CA3179441A1 (https=)
GB (2) GB202007842D0 (https=)
TW (1) TW202210503A (https=)
WO (1) WO2021239812A1 (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7436383B2 (ja) 2018-04-18 2024-02-21 ユーシーエル ビジネス リミテッド 操作された調節性ｔ細胞
TW202321286A (zh) 2021-09-21 2023-06-01 英商圭爾醫療有限公司 抗p75ntr嵌合抗原受體
EP4405385A1 (en) 2021-09-21 2024-07-31 Quell Therapeutics Limited Anti-trem2 chimeric antigen receptor
GB202117298D0 (en) 2021-11-30 2022-01-12 Quell Therapeutics Ltd Signalling protein
US20250017967A1 (en) 2021-12-17 2025-01-16 Quell Therapeutics Limited Anti-thymocyte globulin for immunomodulation of a subject with regulatory t cells
EP4453022A1 (en) 2021-12-22 2024-10-30 Quell Therapeutics Limited Constitutive cytokine receptors
EP4496883A1 (en) 2022-03-22 2025-01-29 Quell Therapeutics Limited Methods and products for culturing t cells and uses thereof
JP2025515134A (ja) * 2022-05-04 2025-05-13 アーリ インコーポレイテッド 疾患細胞の位置を決定するおよび／または疾患細胞を処置するために表面発現可能な活性化可能エピトープを使用する方法
GB202217541D0 (en) 2022-11-24 2023-01-11 Quell Therapeutics Ltd Recombinant receptor
WO2024133472A1 (en) 2022-12-22 2024-06-27 Quell Therapeutics Limited Constitutive cytokine receptors
EP4403580A1 (en) 2023-01-23 2024-07-24 Medizinische Hochschule Hannover Anti-entpd3 chimeric antigen receptor
CN120981484A (zh) 2023-01-23 2025-11-18 汉诺威医学院 抗entpd3嵌合抗原受体
AU2024219048A1 (en) 2023-02-07 2025-08-07 Quell Therapeutics Limited Culture method for treg cells
WO2024175805A1 (en) 2023-02-24 2024-08-29 Medizinische Hochschule Hannover Chimeric antigen receptor
EP4420676A1 (en) 2023-02-24 2024-08-28 Medizinische Hochschule Hannover Chimeric antigen receptor
EP4434539A1 (en) 2023-03-20 2024-09-25 Medizinische Hochschule Hannover Chimeric antigen receptor
WO2024194355A1 (en) 2023-03-20 2024-09-26 Medizinische Hochschule Hannover Chimeric antigen receptor
WO2024194649A1 (en) 2023-03-22 2024-09-26 Quell Therapeutics Limited Engineered t cells and uses thereof
WO2024194642A1 (en) 2023-03-22 2024-09-26 Quell Therapeutics Limited Engineered t regulatory cell
EP4442322A1 (en) 2023-04-06 2024-10-09 Medizinische Hochschule Hannover Liver-specific car for use against immunologic rejection
CN121586727A (zh) 2023-06-21 2026-02-27 圭尔医疗有限公司 组成型细胞因子受体
EP4512415A1 (en) 2023-08-24 2025-02-26 Medizinische Hochschule Hannover Chimeric antigen receptor for treatment of multiple sclerosis or alzheimer's disease
WO2025040799A1 (en) 2023-08-24 2025-02-27 Medizinische Hochschule Hannover Car for treatment of ms or ad
WO2026008994A1 (en) 2024-07-04 2026-01-08 Quell Therapeutics Limited Expression construct
EP4678187A1 (en) 2024-07-11 2026-01-14 Medizinische Hochschule Hannover Compound for use in the treatment of inflammatory bowel disease
WO2026027876A1 (en) 2024-07-29 2026-02-05 Quell Therapeutics Limited Chimeric antigen receptor
GB202411558D0 (en) 2024-08-06 2024-09-18 Quell Therapeutics Ltd Culture method

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0752248T3 (da) 1992-11-13 2000-11-13 Idec Pharma Corp Terapeutisk anvendelse af kimæriske og radioaktivt mærkede antistoffer mod humant B-lymfocytbegrænset differentieringsantig
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
JP2007515946A (ja) 2003-06-13 2007-06-21 オンコマックス アクイジション コーポレイション 抗腫瘍二元機能融合タンパク質の調製および適用
NZ544924A (en) 2003-06-27 2009-03-31 Biogen Idec Inc Modified binding molecules comprising connecting peptides
BRPI0610203A2 (pt) 2005-05-24 2010-06-01 Avestha Gengraine Tech Pvt Ltd processo de preparação in vivo de anti-corpo monoclonal anti-cd 20 biologicamente ativo e composição farmacêutica
GB201206559D0 (en) * 2012-04-13 2012-05-30 Ucl Business Plc Polypeptide
GB201415344D0 (en) * 2014-08-29 2014-10-15 Ucl Business Plc Protein
BR112017013981A2 (pt) * 2015-01-26 2018-01-02 Cellectis receptores antigênicos quiméricos com uma única cadeia específicos anti-cll1 (sccars) para imunoterapia de câncer
US10294304B2 (en) * 2015-04-13 2019-05-21 Pfizer Inc. Chimeric antigen receptors targeting B-cell maturation antigen
US10604586B2 (en) 2016-05-09 2020-03-31 Industrial Technology Research Institute Humanized monoclonal antibody and uses thereof
AU2018246377B2 (en) * 2017-03-31 2025-01-30 Cellectis Sa Universal anti-CD22 chimeric antigen receptor engineered immune cells
AU2019250692A1 (en) * 2018-04-13 2020-11-05 Sangamo Therapeutics France Chimeric antigen receptor specific for Interleukin-23 receptor
CN112996819B (zh) * 2018-08-16 2025-11-04 纪念斯隆-凯特琳癌症中心 细胞分选系统及使用方法
GB201814203D0 (en) 2018-08-31 2018-10-17 King S College London Engineered regulatory t cell

Also Published As

Publication number Publication date
US20230183311A1 (en) 2023-06-15
JP2023527049A (ja) 2023-06-26
GB202218768D0 (en) 2023-01-25
AU2021279184A1 (en) 2022-12-22
CN115955977A (zh) 2023-04-11
EP4157318A1 (en) 2023-04-05
GB2611448A (en) 2023-04-05
GB2611448B (en) 2025-01-08
GB202007842D0 (en) 2020-07-08
WO2021239812A1 (en) 2021-12-02
CA3179441A1 (en) 2021-12-02

Similar Documents

Publication Publication Date Title
TW202210503A (zh) 用於過繼細胞療法之多肽
US20250270279A1 (en) Polypeptide useful in adoptive cell therapy
JP7519906B2 (ja) ホスホリパーゼａ２受容体キメラ自己受容体ｔ細胞の組成物および方法
JP2024024014A (ja) 受容体
CN107532174A (zh) 转座酶多肽及其用途
KR20160067177A (ko) 키메라 항원 수용체
RS62870B1 (sr) Himerni antigenski receptori sa ciljanim delovanjem na receptore spregnute sa g-proteinom i njihove upotrebe
ES2749903T3 (es) Proteína quimérica
JP7404331B2 (ja) 膜結合型ＩＬ－１０をコードする核酸分子及びそれを発現する遺伝子的にリプログラミングされたＴｒｅｇ
TW202227469A (zh) 用於在細胞中表現多肽之核酸構築體
CN115427440A (zh) 用于工程化细胞的嵌合受体
CN119053618A (zh) 嵌合ilt受体组合物和方法
US20240301028A1 (en) Chimeric hla accessory receptor
JP2022533092A (ja) アセチルコリン受容体キメラ自己抗体受容体細胞の組成物および方法
US20210179686A1 (en) Cell sorting systems and methods of use
US20250073265A1 (en) Compositions and Methods of Chimeric Autoantibody Receptor Cells Expressing Extended Phospholipase A2 Receptor Fragments
CN121586727A (zh) 组成型细胞因子受体
WO2023237541A1 (en) Delta t-cell or gamma t-cell receptor chains or parts thereof that mediate an anti-tumour or anti-infective response